Response to Abemaciclib in the neoMONARCH Trial

December 7, 2018
Sara A. Hurvitz, MD

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses response to abemaciclib (Verzenio) in the neoMONARCH trial at the 2018 San Antonio Breast Cancer Symposium.

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses response to abemaciclib (Verzenio) in the neoMONARCH trial at the 2018 San Antonio Breast Cancer Symposium.

The neoMONARCH trial is a neoadjuvant study evaluating 3 different treatment arms in patients with early-stage, estrogen receptor—positive, HER2-negative breast cancer. Patients are given anastrozole for 2 weeks, abemaciclib for 2 weeks, or the combination of the 2 for 14 weeks. This was a biomarker-driven study in which tumor biopsies were obtained at baseline, as well as after 2 weeks and 14 weeks of therapy, explains Hurvitz.